Assessing age of onset and clinical symptoms over time in patients with heterozygous pathogenic DHDDS variants
Journal of Inherited Metabolic Disease · 2024
DOI: 10.1002/jimd.12769 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, 2024. Verfasst von I J J Muffels und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Age of Onset, Heterozygote. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: NINDS NIH HHS, NCATS NIH HHS, Rare Diseases Clinical Research Network.
Abstract (Originalsprache)
Mono‐allelic DHDDS variants are associated with seizures, intellectual disability, and movement disorders. The age of onset and progression rates of symptoms vary greatly among patients, spanning from infancy to late adulthood. Yet, the reasons behind this clinical variability and the underlying pathophysiological mechanisms of the disease have remained elusive. We investigated the age of onset and the progression of symptoms over time in 59 patients with heterozygous DHDDS variants, drawing from medical literature and incorporating five previously unreported cases from the FCDGC Natural History Study. Clinical symptoms typically emerged early in life. Ataxia, tremor, dystonia, and dyskinesia manifested slightly later in childhood. Global developmental delay usually presented as the initial symptom. We observed diverse rates of symptom accumulation over time: some patients exhibited the full spectrum of symptoms in early childhood, while others developed novel symptoms well into adulthood. Interestingly, neither the sex nor the underlying DHDDS variants correlated with the age of symptom onset or specific clinical symptoms. Additionally, we found that 19% of patients presented with autism spectrum disorder. This study offers insight into the age of symptom onset and the rate of symptom accumulation in patients with DHDDS variants. We found no correlation between the age of onset and progression of clinical symptoms with specific DHDDS variants or patient sex. Autism spectrum disorder is common in patients and warrants attention in clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Anatomy, University of Pecs Medical School, Pecs, Hungary.
- Department of Biophysics, University of Pecs Medical School, Pecs, Hungary.
ORCID-Profile: I J J Muffels, T Kozicz, E Morava
Förderung
- NINDS NIH HHS
- NCATS NIH HHS
- Rare Diseases Clinical Research Network
- National Institute of Child Health and Human Development
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Muffels, I. J. J., Sadek, M., Kozicz, T., & Morava, E. (2024). Assessing age of onset and clinical symptoms over time in patients with heterozygous pathogenic DHDDS variants. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12769
Vancouver
Muffels IJJ, Sadek M, Kozicz T, Morava E. Assessing age of onset and clinical symptoms over time in patients with heterozygous pathogenic DHDDS variants. Journal of Inherited Metabolic Disease. 2024. doi:10.1002/jimd.12769
BibTeX
@article{Muffels2024,
author = {Muffels, I J J and Sadek, M and Kozicz, T and Morava, E},
title = {Assessing age of onset and clinical symptoms over time in patients with heterozygous pathogenic DHDDS variants},
journal = {Journal of Inherited Metabolic Disease},
year = {2024},
doi = {10.1002/jimd.12769}
}
EUVIMED